Boothbay Fund Management’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Boothbay Fund Management’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-22,200	Closed	-$2.26M	–	2223
2023 Q2	$2.26M	Buy	22,200 +1,900	+9%	+$180K	0.05%	510
2023 Q1	$1.85M	Buy	+20,300	New	+$1.19M	0.04%	704
2022 Q4	–	Sell	-18,600	Closed	-$467K	–	2592
2022 Q3	$467K	Sell	18,600 -1,900	-9%	-$52.7K	0.01%	1274
2022 Q2	$623K	Buy	+20,500	New	+$612K	0.02%	1065
2022 Q1	–	Sell	-21,800	Closed	-$575K	–	2635
2021 Q4	$575K	Buy	21,800 +10,900	+100%	+$843K	0.01%	955
2021 Q3	$1.1M	Buy	+10,900	New	+$1.28M	0.03%	722
2020 Q4	–	Sell	-133	Closed	-$1.3M	–	1479
2020 Q3	$1.3M	Sell	133 -77	-37%	-$9.62K	0.08%	352
2020 Q2	$3.28M	Buy	+210	New	+$31.9K	0.22%	103
2019 Q4	–	Sell	-87	Closed	-$699K	–	1045
2019 Q3	$699K	Buy	+87	New	+$7.38K	0.06%	388
2018 Q4	–	Sell	-163	Closed	-$1.33M	–	959
2018 Q3	$1.33M	Buy	+163	New	+$11.5K	0.13%	150

Other funds holding RETA

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Boothbay Fund Management's RETA Position: Q2 2023 in Review

Boothbay Fund Management sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q2 2023, closing a stake of 16,154 shares — an estimated $1.53M sold.

Boothbay Fund Management first reported a position in RETA in Q4 2020 and held it in 3 quarters. The position peaked at $1.47M in Q1 2023. 214 funds tracked by Wall St. Rank hold RETA as of Q2 2023.

Boothbay Fund Management reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q2 2023 after selling out during the quarter.
Boothbay Fund Management sold 16,154 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q2 2023, an estimated $1.53M.
Boothbay Fund Management first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q4 2020 and held it in 3 quarters.
Boothbay Fund Management's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $1.47M in Q1 2023.
214 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q2 2023.

Based on Boothbay Fund Management's 13F filing for Q2 2023, filed 14 Aug 2023.